Search

Your search keyword '"Nogova, L."' showing total 270 results
Start Over Author "Nogova, L."
270 results on '"Nogova, L."'

1. Overall survival and central nervous system activity of crizotinib in ROS1-rearranged lung cancer—final results of the EUCROSS trial

Author

Michels, S., Massutí, B., Vasyliv, I., Stratmann, J., Frank, J., Adams, A., Felip, E., Grohé, C., Rodriguez-Abreu, D., Bischoff, H., Carcereny i Costa, E., Corral, J., Pereira, E., Fassunke, J., Fischer, R.N., Insa, A., Koleczko, S., Nogova, L., Reck, M., Reutter, T., Riedel, R., Schaufler, D., Scheffler, M., Weisthoff, M., Provencio, M., Merkelbach-Bruse, S., Hellmich, M., Sebastian, M., Büttner, R., Persigehl, T., Rosell, R., and Wolf, J.

Published
2024
Full Text
View/download PDF

2. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer

Author

Kron, A., Alidousty, C., Scheffler, M., Merkelbach-Bruse, S., Seidel, D., Riedel, R., Ihle, M.A., Michels, S., Nogova, L., Fassunke, J., Heydt, C., Kron, F., Ueckeroth, F., Serke, M., Krüger, S., Grohe, C., Koschel, D., Benedikter, J., Kaminsky, B., Schaaf, B., Braess, J., Sebastian, M., Kambartel, K -O, Thomas, R., Zander, T., Schultheis, A.M., Büttner, R., and Wolf, J.

Published
2018
Full Text
View/download PDF

3. 9P Small-scale ROS1 aberrations: Functional impact and therapeutic potential

Author

Glaser, M., primary, von Levetzow, C., additional, Michels, S., additional, Nogova, L., additional, Katzenmeier, M., additional, Wömpner, C., additional, Schmitz, J., additional, Bitter, E., additional, Terjung, I., additional, Passmann, E., additional, Schaufler, D., additional, Eisert, A., additional, Fischer, R.N., additional, Riedel, R., additional, Hahne, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Wolf, J., additional, and Scheffler, M., additional

Published
2022
Full Text
View/download PDF

4. EP08.02-114 Comprehensive Analysis of ROS1 Aberrations without Rearrangements in Non-small cell Lung Cancer Patients

Author

Glaser, M., primary, von Levetzow, C., additional, Michels, S., additional, Nogova, L., additional, Katzenmeier, M., additional, Wömpner, C., additional, Schmitz, J., additional, Bitter, E., additional, Terjung, I., additional, Passmann, E., additional, Schaufler, D., additional, Eisert, A., additional, Fischer, R., additional, Riedel, R., additional, Weber, J.-P., additional, Hahne, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Wolf, J., additional, and Scheffler, M., additional

Published
2022
Full Text
View/download PDF

5. EP08.02-106 KEAP1/NFE2L2 Transcriptomic Signature Predicts Survival in Advanced Stage NSCLC Patients Without Actionable Driver Mutations

Author

Scheffler, M., primary, Dugan, M., additional, Saleh, M.M., additional, Koleczko, S., additional, Brägelmann, J., additional, Arolt, C., additional, Nogova, L., additional, Riedel, R., additional, Michels, S., additional, Eisert, A., additional, Fischer, R., additional, Scharpenseel, H., additional, Weber, J.-P., additional, Scheel, A.H., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Lafleur, F., additional, Wild, R., additional, Catanzariti, L., additional, Hillmer, A.M., additional, and Wolf, J., additional

Published
2022
Full Text
View/download PDF

6. 991P EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

Author

Kron, A., primary, Scheffler, M., additional, Ihle, M., additional, Michels, S., additional, Süptitz, J., additional, Prang, D., additional, Jakobs, F., additional, Nogova, L., additional, Fischer, R.N., additional, Eisert, A.K., additional, Riedel, R., additional, Kron, F., additional, Hillmer, A., additional, Loges, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, and Wolf, J., additional

Published
2022
Full Text
View/download PDF

7. 1028P BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response – results from the NSCLC cohort

Author

Fischer, R.N., primary, George, J., additional, Scheel, A., additional, Schloesser, H., additional, Brossart, P., additional, Engel-Riedel, W., additional, Griesinger, F., additional, Grohé, C., additional, Kern, J.K., additional, Panse, J., additional, Sebastian, M., additional, Serke, M., additional, Wiewrodt, R., additional, Michels, S., additional, Nogova, L., additional, Riedel, R., additional, Weber, J-P., additional, Büttner, R., additional, Thomas, R., additional, and Wolf, J., additional

Published
2022
Full Text
View/download PDF

8. 1729P The biological effect of small-scale ROS1 aberrations: An in silico analysis

Author

Glaser, M., primary, von Levetzow, C., additional, Michels, S., additional, Nogova, L., additional, Katzenmeier, M., additional, Wömpner, C., additional, Schmitz, J., additional, Bitter, E., additional, Terjung, I., additional, Passmann, E., additional, Schaufler, D., additional, Eisert, A.K., additional, Fischer, R.N., additional, Riedel, R., additional, Weber, J-P., additional, Hahne, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Wolf, J., additional, and Scheffler, M., additional

Published
2022
Full Text
View/download PDF

9. P13.03.A Radiomics for the non-invasive assessment of the PDL-1 expression in patients with non-small cell lung cancer brain metastases

Author

Meißner, A, primary, Gutsche, R, additional, Galldiks, N, additional, Kocher, M, additional, Jünger, S, additional, Eich, M, additional, Nogova, L, additional, Schmidt, N, additional, Ruge, M, additional, Goldbrunner, R, additional, Proescholdt, M, additional, Grau, S, additional, and Lohmann, P, additional

Published
2022
Full Text
View/download PDF

10. KS02.7.A Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors

Author

Ceccon, G S, primary, Werner, J, additional, Ruge, M I, additional, Goldbrunner, R, additional, Celik, E, additional, Baues, C, additional, Deckert, M, additional, Brunn, A, additional, Büttner, R, additional, Golla, H, additional, Nogova, L, additional, Schlamann, M, additional, Kabbasch, C, additional, Rueß, D, additional, Hampl, J, additional, Wollring, M, additional, Bauer, E K, additional, Tscherpel, C, additional, Fink, G R, additional, Langen, K, additional, and Galldiks, N, additional

Published
2022
Full Text
View/download PDF

12. The fading relevance of the quantity of brain metastases in patients with non-small cell lung cancer

Author

Reinecke, D, Jünger, ST, Kocher, M, Nogova, L, Eich, ML, Ruge, MI, Rueß, D, Goldbrunner, R, and Grau, S

Subjects
ddc: 610, Medicine and health
Abstract

Objective: That the number of brain metastases (BM) is included in prognostic assessment models for patients with non-small cell lung cancer (NSCLC). However, the underlying data were generated in an era with limited systemic treatment options. With rapidly changing treatment modalities based on a growing [for full text, please go to the a.m. URL]

Published
2022
Full Text
View/download PDF

15. Impact of FET PET on multidisciplinary neurooncological tumor board decisions in patients with brain tumors

Author

Ceccon, G. S., Werner, J., Ruge, M., I, Goldbrunner, R., Celik, E., Baues, C., Deckert, M., Brunn, A., Buttner, R., Golla, H., Nogova, L., Schlamann, M., Kabbasch, C., Ruess, D., Hampl, J., Wollring, M., Bauer, E. K., Tscherpel, C., Fink, G. R., Langen, K., Galldiks, N., Ceccon, G. S., Werner, J., Ruge, M., I, Goldbrunner, R., Celik, E., Baues, C., Deckert, M., Brunn, A., Buttner, R., Golla, H., Nogova, L., Schlamann, M., Kabbasch, C., Ruess, D., Hampl, J., Wollring, M., Bauer, E. K., Tscherpel, C., Fink, G. R., Langen, K., and Galldiks, N.

Published
2022

16. EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB)

Author

Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R., and Wolf, J.

Published
2022

17. ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

Author

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., Scheffler, M., Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., and Scheffler, M.

Published
2022

18. The biological effect of small-scale ROS1 aberrations: An in silico analysis

Author

Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J., Scheffler, M., Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J., and Scheffler, M.

Published
2022

19. Small-scale ROS1 aberrations: Functional impact and therapeutic potential

Author

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., Scheffler, M., Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J., and Scheffler, M.

Published
2022

20. BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort

Author

Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R., Wolf, J., Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R., and Wolf, J.

Published
2022

21. 52P ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics

Author

Glaser, M., primary, von Levetzow, C., additional, Michels, S., additional, Nogova, L., additional, Katzenmeier, M., additional, Wömpner, C., additional, Schmitz, J., additional, Bitter, E., additional, Terjung, I., additional, Passmann, E., additional, Schaufler, D., additional, Eisert, A., additional, Fischer, R., additional, Riedel, R., additional, Weber, J-P., additional, Hahne, S., additional, Merkelbach-Bruse, S., additional, Büttner, R., additional, Wolf, J., additional, and Scheffler, M., additional

Published
2022
Full Text
View/download PDF

24. 1431P The nNGM Preclinical Platform: Preclinical research to generate evidence for patients with non-small cell lung cancer harboring variants of unknown significance

Author

Ziegler, M., Albers-Leischner, C., Salgueiro, L., Khoury, N., Sharapova, Y., Saalfeld, F.C., Wenzel, C., Scharpenseel, H., Schmidt, C., Naveja-Romero, J., Meemboor, S., Hillmer, A., Nogova, L., Wermke, M., Wolf, J., Diederichs, S., Brummer, T., Büttner, R., Janning, M., and Loges, S.

Published
2023
Full Text
View/download PDF

30. MIMEB: A phase II trial to evaluate FDG-PET/FLT-PET and DCE-MRI for early prediction of efficacy in patients with advanced non-small cell lung cancer treated with erlotinib and bevacizumab: ID 439

Author

Scheffler, M., Bos, M., Sos, M., Nogova, L., Gardizi, M., Mattonet, C., Papachristou, I., Kahraman, D., Kobe, C., Lammertsma, A., Boellaard, R., Persigehl, T., Heukamp, L., Büttner, R., Elter, T., Töpelt, K., Engel-Riedel, W., Stoelben, E., Neumaier, B., Dietlein, M., Zander, T., and Wolf, J.

Published
2014

34. EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data

Author

Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R., Wolf, J., Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R., and Wolf, J.

Published
2020

35. Small Cell Lung Cancer - Filling the gap between science and patients

Author

Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R., Wolf, J., Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R., and Wolf, J.

Published
2020

36. KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup

Author

Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R., Wolf, J., Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R., and Wolf, J.

Published
2020

37. FIND: a phase II study to evaluate the efficacy of erdafitinib in FGFR-altered NSCLC

Author

Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R., Wolf, J., Nogova, L., Malchers, F., Hillmer, A. M., Merkelbach-Bruse, S., Pinto, A., Scheel, A. H., Siemanowski, J., Ueckeroth, F., Scheffler, M., Hummel, H. -D., Kern, J., Wermke, M., Kolbe, M., Grohe, C., Stratmann, J., Sebastian, M., Trummer, A., Weber, J. -P., Westphal, T., Michels, S., Koleczko, S., Sueptitz, J., Keser, E., Kron, A., Riedel, R., Abdulla, D. S. Y., Zadoyan, G., Sweiti, H., Santiago-Walker, A., Rothe, A., Draube, A., Sandler, A., Rodermann, E., Linck, D., Thomas, R. K., Buettner, R., and Wolf, J.

Published
2020

38. FP14.04 Resistance to MET Inhibition in MET Driven NSCLC and Response after Switching from Type I to Type II MET Inhibitors

Author

Riedel, R., primary, Heydt, C., additional, Scheel, A., additional, Tumbrink, H., additional, Brägelmann, J., additional, Fassunke, J., additional, Nogova, L., additional, Michels, S., additional, Scheffler, M., additional, Fischer, R., additional, Koleczko, S., additional, Weber, J., additional, Westphal, T., additional, Abdulla, D., additional, Merkelbach-Bruse, S., additional, Sos, M., additional, Büttner, R., additional, and Wolf, J., additional

Published
2021
Full Text
View/download PDF

47. EATON: An open-label, multicenter, phase I dose-escalation trial of nazartinib (EGF816) and trametinib in patients with EGFR-mutant non-small cell lung cancer - preliminary data on safety and tolerability

Author

Michels, S, Nogova, L, Deschler-Baier, B, Sebastian, M, Schuler, M, Wermke, M, Felip, E, Rodriguez-Abreu, D, Rosell, R, Abdulla, DSY, Fischer, RN, Koleczko, S, Kron, A, Pinto, A, Riedel, R, Scheffler, M, Suptitz, J, Fassunke, J, Merkelbach-Bruse, S, Hellmich, M, Buttner, R, and Wolf, J

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results